Methadone N-demethylation in human liver microsomes: Lack of stereoselectivity and involvement of CYP3A4

British Journal of Clinical Pharmacology

Volumn 47, Issue 4, 1999, Pages 403-412

  Foster, David J R ^a   Somogyi, Andrew A ^a   Bochner, Felix ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

CYP3A4; EDDP formation; Human liver microsomes; Methadone N demethylation; Stereoselectivity

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DEBRISOQUINE 4 HYDROXYLASE; DIETHYLTHIOCARBAMATE; DIMETHYLNITROSAMINE DEMETHYLASE; ENZYME INHIBITOR; FURAFYLLINE; KETOCONAZOLE; MEPHENYTOIN; METHADONE; MONOCLONAL ANTIBODY; OPIATE AGONIST; PHENACETIN O DEETHYLASE; QUINIDINE; SULFAPHENAZOLE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL; STEREOCHEMISTRY;

ADULT; AGED; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; FEMALE; HUMANS; METHADONE; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NARCOTICS; STEREOISOMERISM;

EID: 0032903876     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00921.x     Document Type: Article

References (44)

1. 1 Kristensen K, Christensen CB, Christrup LL. The mu1, mn2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 1995; 56: 45-50.
2. 2 Scott CC, Robbins EB, Chen KK. Pharmacologic comparison of the optical isomers of methadon. J Pharmacol Exp Ther 1948; 93: 282-286.
3. 3 Isbell H, Eisenman AJ. The addiction liability of some of the drugs of the methadon series. Fed Proc 1948; 7: 162.
4. 4 Kristensen K, Blemmer T, Angelo HR, et al. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 1996; 18: 221-227.
5. 5 Eap CB, Cuendet C, Baumann P. Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. Clin Pharmacol Ther 1990; 47: 338-346.
6. 6 Romach MK, Piafsky KM, Abel JG, Khouw V, Sellers EM. Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma. Clin Pharmacol Ther 1981; 29: 211-217.
7. 7 Sullivan HR, Smits SE, Due SL, Booher RE, McMahon RE. Metabolism of d-methadone: Isolation and identification of analgesically active metabolites. Life Sci 1972; 11: 1093-1104.
8. 8 Sullivan HR, Duc SL. Urinary metabolites of dl-methadone in maintenance subjects. J Med Chem 1973; 16: 909-913.
9. 9 Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 1985; 233: 1-6.
10. 10 Änggård E, Gunne LM, Homstrand J, McMahon RE, Sandberg CG, Sullivan HR. Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 1975; 17: 258-266.
11. 11 Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9: 365-373.
12. 12 Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicol 1997; 117: 13-23.
13. 13 Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998; 26: 257-260.
14. 14 Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P450 3A4 in the N demethylation of 1-alpha acetylmethadol (laam), norlaam, and methadone. Drug Metab Dispos 1997; 25: 1347-1353.
15. 15 Zanger UM, Vilbois F, Hardwick JP, Meyer UA. Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988; 27: 5447-5454.
16. 16 Lowry OH, Roseburg NJ, Farr AL, Randall RJ. Measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.
17. 17 Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes, II Solubilisation, purification and properties. J Biol Chem 1964; 234: 2374-2385.
18. 18 Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long PCR technology. Pharmacogenetics 1995; 5: 215-223.
19. 19 Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529-532.
20. 20 Coller JK, Somogyi AA, Bochner F. Association between CYP2C19 genotype and proguanil oxidative polymorphism. Br J Clin Pharmacol 1997; 43: 659-660.
21. 21 Newton DJ, Wang RW, Lu AY. Cytochrome P 450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
22. 22 Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38: 131-137.
23. 23 von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramme hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15: 125-131.
24. 24 Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997; 70: 109-115.
25. 25 Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-123.
26. 26 Shimada T, Yamazaki H, Mimura M, et al. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos 1996; 24: 515-522.
27. 27 Kuhn KL, Halikas JA, Kemp KD. Carbamazepine treatment of cocaine dependence in methadone maintenance patients with dual opiate-cocaine addiction. NIDA Res Monogr 1989; 95: 316-317.
28. 28 Saxon AJ, Whittaker S, Hawker CS. Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolisin: two cases. J Clin Psychiatry 1989; 50: 228-229.
29. 29 Tong TG, Pond SM, Kreek MJ, Jaffery NF, Benowitz NL. Phenytoin-induced methadone withdrawral. Ann Intern Med 1981; 94: 319-351.
30. 30 Liu SJ, Wang RI. Case report of barbiturate induced enhancement of methadone metabolism and withdrawal syndrome. Am J Psychiatry 1984; 141: 1287-1288.
31. 31 Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone withdrawal. N Engl J Med 1976; 294: 1104-1106.
32. 32 Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse 1990; 16: 329-336.
33. 33 Maany I, Dhopesh V, Arndt IO, Burke W, Woody G, O'Brien CP. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry 1989; 146: 1611-1613.
34. 34 Kerry NL, Somogyi AA, Bochner F, Mikus G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol 1994; 38: 243-248.
35. 35 Wu D, Otton SV, Sproule BA, et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Phamacol 1993; 35: 30-34.
36. 36 Otton SV, Brinn RU, Gram LF. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. Drug Metab Dispos 1988; 16: 15-17.
37. 37 Chang TK, Gonzalez FJ, Waxman DJ. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 1994; 311: 437-442.
38. 38 Pond SM, Tong TG, Benowitz NL, Jacob PD, Rigod J. Lack of effect of diazepam on methadone metabolism in methadone-maintained addicts. Clin Pharmacol Ther 1982; 31: 139-143.
39. 39 Preston KL, Griffiths RR, Cone EJ, Darwin WD, Gorodetzky CW. Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug Alcohol Depend 1986; 18: 195-202.
40. 40 von Moltke LL, Greenblatt DJ, Cotreau Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31.
41. 41 Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 311-320.
42. 42 Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994; 37: 597-604.
43. 43 Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-530.
44. 44 Ko J-W, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-862.